Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
| dc.contributor.author | Kilickap, S. | |
| dc.contributor.author | Ozturk, A. | |
| dc.contributor.author | Karadurmus, N. | |
| dc.contributor.author | Korkmaz, T. | |
| dc.contributor.author | Yumuk, P. | |
| dc.contributor.author | Cicin, I. | |
| dc.contributor.author | Paydas, S. | |
| dc.contributor.author | Cilbir, E. | |
| dc.contributor.author | Sakalar, T. | |
| dc.contributor.author | Uysal, M. | |
| dc.contributor.author | Uskent, N. | |
| dc.contributor.author | Demir, N. | |
| dc.contributor.author | Sakin, A. | |
| dc.contributor.author | Turhal, N. | |
| dc.contributor.author | Keskin, S. | |
| dc.contributor.author | Tural, D. | |
| dc.contributor.author | Eralp, Y. | |
| dc.contributor.author | Basal, F. | |
| dc.contributor.author | Yasar, H. | |
| dc.contributor.author | Sendur, M. A. | |
| dc.contributor.author | Demirci, U. | |
| dc.contributor.author | Cubukcu, E. | |
| dc.contributor.author | Karaagac, M. | |
| dc.contributor.author | Karaca, S. | |
| dc.contributor.author | Tatli, A. | |
| dc.contributor.author | Yetisyigit, T. | |
| dc.contributor.author | Urvay, S. | |
| dc.contributor.author | Gursoy, P. | |
| dc.contributor.author | Uluc, B. Oyan | |
| dc.contributor.author | Turna, Z. | |
| dc.contributor.author | Kucukoner, M. | |
| dc.contributor.author | Olmez, O. | |
| dc.contributor.author | Cabuk, D. | |
| dc.contributor.author | Seker, M. | |
| dc.contributor.author | Unal, O. | |
| dc.contributor.author | Meydan, N. | |
| dc.contributor.author | Okutur, S. | |
| dc.contributor.author | Tunali, D. | |
| dc.date.accessioned | 2019-10-27T10:01:26Z | |
| dc.date.available | 2019-10-27T10:01:26Z | |
| dc.date.issued | 2018 | |
| dc.department | Ege Üniversitesi | en_US |
| dc.identifier.endpage | S478 | en_US |
| dc.identifier.issn | 1556-0864 | |
| dc.identifier.issn | 1556-1380 | |
| dc.identifier.issue | 10 | en_US |
| dc.identifier.startpage | S477 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11454/29848 | |
| dc.identifier.volume | 13 | en_US |
| dc.identifier.wos | WOS:000454014501235 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier Science Inc | en_US |
| dc.relation.ispartof | Journal of Thoracic Oncology | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | NSCLC | en_US |
| dc.subject | ALK inhibitor | en_US |
| dc.subject | crizotinib | en_US |
| dc.title | Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey | en_US |
| dc.type | Conference Object | en_US |
